Novavax, Inc.Long
Vaccine race
Updated
The big stories in the new year, though, could come from vaccines that haven't made it to market yet. It's possible that the stocks of the companies developing these experimental vaccines will deliver tremendous gains over the next 12 months. Here are four coronavirus stocks that are especially poised to soar in 2021.
Of course, they are could be very volatile and uncertain because of the licencing. They are in phase 2 or 3.
Innovio(INO) a small-cap company. It maybe has found its bottom and their vaccine has an advantage in that the drug does not need to be frozen, also announced it entered into a collaborative agreement with Chinese company Advaccine Biopharmaceuticals Suzhou. Their vaccine(INO-4800) could be brought to market within Greater China. Inovio's stock could become a great buy if INO-4800 is successful and the Food and Drug Administration (FDA) approves the vaccine. But the problem is that's not a guarantee.
Altimmun(ALT) a small-cap company. Altimmun could regain the high of summer and something getting started. Their vaccine only requires a single dose. It can be stored at room temperature for extended periods.
Vaxart(VXRT) is a small-cap company. Found its bottom in a sideways consolidation and now something makes investor interested by the last day momentum. Their vaccine could be really cool because It's a single-dose tablet instead of an injection. That makes Vaxart's vaccine more convenient to take and to distribute and store.
Novavax(Nvax) is a mid-cap company. Novavax has a COVID-19/flu combo vaccine. It makes me interested in and I like the sideways consolidation last month or more. Now I waiting for an upward break and it could reach a high of 200 or more.
These forecasts were created to support you, but you have to make your trading decisions independently! Which one could be the winner or loser? Who knows? As nobody sees the future, I recommend you that always apply risk management during your trading and highly recommend the diversification!
Of course, they are could be very volatile and uncertain because of the licencing. They are in phase 2 or 3.
Innovio(INO) a small-cap company. It maybe has found its bottom and their vaccine has an advantage in that the drug does not need to be frozen, also announced it entered into a collaborative agreement with Chinese company Advaccine Biopharmaceuticals Suzhou. Their vaccine(INO-4800) could be brought to market within Greater China. Inovio's stock could become a great buy if INO-4800 is successful and the Food and Drug Administration (FDA) approves the vaccine. But the problem is that's not a guarantee.
Altimmun(ALT) a small-cap company. Altimmun could regain the high of summer and something getting started. Their vaccine only requires a single dose. It can be stored at room temperature for extended periods.
Vaxart(VXRT) is a small-cap company. Found its bottom in a sideways consolidation and now something makes investor interested by the last day momentum. Their vaccine could be really cool because It's a single-dose tablet instead of an injection. That makes Vaxart's vaccine more convenient to take and to distribute and store.
Novavax(Nvax) is a mid-cap company. Novavax has a COVID-19/flu combo vaccine. It makes me interested in and I like the sideways consolidation last month or more. Now I waiting for an upward break and it could reach a high of 200 or more.
These forecasts were created to support you, but you have to make your trading decisions independently! Which one could be the winner or loser? Who knows? As nobody sees the future, I recommend you that always apply risk management during your trading and highly recommend the diversification!
Note
INO, Innovio: there is the three white soldiers pattern which is encouraging.Note
Vaxart closed at 18$,
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.